Anbieter: Romtrade Corp., STERLING HEIGHTS, MI, USA
Zustand: New. This is a Brand-new US Edition. This Item may be shipped from US or any other country as we have multiple locations worldwide.
Anbieter: Majestic Books, Hounslow, Vereinigtes Königreich
EUR 126,99
Anzahl: 4 verfügbar
In den WarenkorbZustand: New. pp. 408.
Anbieter: PBShop.store UK, Fairford, GLOS, Vereinigtes Königreich
EUR 134,51
Anzahl: 15 verfügbar
In den WarenkorbHRD. Zustand: New. New Book. Shipped from UK. Established seller since 2000.
hardcover. Zustand: Sehr gut. 416 Seiten; 9780470170830.2 Gewicht in Gramm: 500.
EUR 160,19
Anzahl: Mehr als 20 verfügbar
In den WarenkorbGebunden. Zustand: New. J. Andrew Williams, PHD, is Director of Translational Oncology at Pfizer Oncology.Richard Lalonde, PharmD, is Vice President and Global Head of Clinical Pharmacology at Pfizer.Jeffrey Koup, PharmD, is a consultant for PKPD modeling and the owner of Lakeside.
Anbieter: Revaluation Books, Exeter, Vereinigtes Königreich
EUR 208,86
Anzahl: 2 verfügbar
In den WarenkorbHardcover. Zustand: Brand New. 1st edition. 408 pages. 9.25x6.50x0.75 inches. In Stock.
EUR 229,87
Anzahl: Mehr als 20 verfügbar
In den WarenkorbZustand: New. Practical Utility of Biomarkers in Drug Discovery and Development covers all aspects of biomarker research applied to drug discovery and development and contains state-of-the-art appraisals on the practical utility of genomic, biochemical, and protein biomarkers. Editor(s): Williams, J. Andrew; LaLonde, Richard J.; Koup, Jeffrey R.; Christ, David D. Series Editor(s): Ekins, Sean. Series: Wiley Series on Technologies for the Pharmaceutical Industry. Num Pages: 408 pages, Illustrations. BIC Classification: KNDP; MMG; TDCW. Category: (P) Professional & Vocational. Dimension: 237 x 159 x 28. Weight in Grams: 716. . 2012. 1st Edition. Hardcover. . . . . Books ship from the US and Ireland.
Anbieter: AHA-BUCH GmbH, Einbeck, Deutschland
Buch. Zustand: Neu. Neuware - Practical Utility of Biomarkers in Drug Discovery and Development covers all aspects of biomarker research applied to drug discovery and development and contains state of the art appraisals on the practical utility of genomic, biochemical, and protein biomarkers. Case histories and lessons from successful and unsuccessful applications of biomarkers are included along with key chapters on GLP validation, safety biomarkers and proteomics biomarkers. Regulatory agency perspectives and initiatives both in the US and internationally are also discussed.